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Summary
Many observations support a major biological effect from the way in which people interpret the meaning of each component of their medical
experience and the context in which this occurs. A recent systematic review of randomised controlled trials in osteoarthritis has demonstrated
that the effect size of ‘‘placebo’’ is substantial and is usually greater than that obtained from the speciﬁc effect of an individual treatment. In the
context of a randomised controlled trial, such a large placebo or ‘‘meaning’’ response is considered a nuisance, but in the context of clinical
practice the optimisation of such meaning and contextual responses, through enhanced ‘‘care’’, could greatly beneﬁt people who suffer from
osteoarthritis.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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We recently published a systematic review and meta-anal-
ysis of placebo response in osteoarthritis (OA) randomised
controlled trials (RCTs)1. This conﬁrmed the appreciable ef-
fect size (ES) of ‘‘placebos’’ on pain relief and identiﬁed
some of the factors that may determine the size of this ef-
fect in RCTs. These ﬁndings clearly are of relevance to
the design of OA RCTs and to the interpretation of the
true ES of treatments. More importantly, however, these re-
sults have important implications for clinical practice. Here
we will: (1) brieﬂy review the history, nomenclature and
changing perspective of ‘‘placebo’’; (2) summarise the ﬁnd-
ings of our meta-analysis; (3) present related key observa-
tions taken largely from the pain and mental health
literature; and ﬁnally (4) explain how this knowledge might
inﬂuence our behaviour as clinicians and the care that we
offer patients with OA.Historical changes in perspective concerning
placebo
Prior to the mid 20th century it was commonplace for doc-
tors to prescribe placebos with the assurance that they
would lead to health and coping beneﬁts2. This deliberate
prescription of inert products was described by Thomas Jef-
ferson in 1807 as the ‘‘pious fraud’’3 and in the Lancet in
1954 as ‘‘humble humbug’’4. However, at a time when there
were few effective treatments such deception was*Address correspondence and reprint requests to: Michael
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Fax: 44-115-8231757; E-mail: michael.doherty@nottingham.ac.uk
Received 17 March 2009; revision accepted 22 March 2009.
1255considered both ethical and benevolent2,4,5. Placebo
means ‘‘I will please’’ and up until the 1950s the prevailing
view was that products such as bread pills, coloured water,
or water injections, would do no harm and by a psychologi-
cal trick could comfort patients with incurable conditions, es-
pecially those low in intellect or ‘‘inadequate’’ and thus more
susceptible to suggestion4,5.
In thesecondquarter of the20th century, however, twopar-
allel developments changed this perspective. Firstly, the ad-
vances in effective drug discovery, and secondly the
developments in medical statistics and epidemiology that
led to introduction of the RCT as the gold standard for clinical
trials. In a landmark publication in 1955 entitled ‘‘The Power-
ful Placebo’’6 Henry Beecher described the occurrence in
RCTs of real, not imagined, objective beneﬁts from placebo
in around 35% of patients. He reasoned that the total beneﬁt
from a treatment equals the ‘‘real’’ or speciﬁc effect of the
treatment plus the non-speciﬁc placebo effect, and impor-
tantly concluded that response to placebo was irrespective
of IQ. Subsequent research focused on how this effect may
arise, and amongst mechanisms suggested were the Haw-
thorne effect (behaviour change through being observed);
patient expectation of improvement; a ‘‘meaning response’’;
classic conditioning; relief of anxiety; contextual healing; re-
sponse bias; and the patientepractitioner interaction2,7,8.
There has been much controversy over the meaning of
the word ‘placebo’ and it is important to distinguish placebo
responses (sometimes called ‘context effects’) from pla-
cebo interventions9. Arguably the most useful deﬁnition of
placebo (and nocebo) effects is that provided by Grun-
baum in the 1980s10,11; he distinguishes the characteristic
effects of an intervention for the target condition, from all
the non-characteristic (or incidental) effects related to the
use of that intervention. Thus, for example, a sugar pill
might be used as a placebo tablet in a trial of an
1256 M. Doherty and P. Dieppe: ‘‘Placebo’’ response in OA e implications for clinical practiceantidepressant drug since sugar is not thought to have any
speciﬁc (characteristic) effect on depression e but the
same could not be said for diabetes. And if a sugar pill pla-
cebo was used in a trial of antidepressant therapy, then its
effects will depend on a huge number of contextual factors
surrounding its administration, as outlined below. Paterson
and Dieppe have pointed out that in many complex inter-
ventions used for conditions such as OA these non-charac-
teristic (context) effects may interact with the characteristic
effects9. This not only makes it more difﬁcult to interpret the
results of trials, it can invalidate the use of the classical
RCT as a way of assessing the value of such interventions
(Fig. 1).
At the turn of this century the existence of placebo re-
sponse was challenged. In a systematic review of RCTs
that randomised participants to either placebo or no treat-
ment (observation only), Hrobjartsson and Gotzsche found
no signiﬁcant beneﬁt from placebo for binary or objective
outcomes, but possible small beneﬁts for continuous sub-
jective outcomes and for the treatment of pain12. Although
there were many problems with this review and its
methodology was seriously challenged13,14, this publication
rekindled the debate about placebos. Alternative explana-
tions for apparent placebo beneﬁts in RCTs included un-
measured concomitant treatments and the patient’s
desire to please the doctor (the ‘‘patient’s placebo’’), but
also impersonal statistical artefacts of measurement such
as natural ﬂuctuations in disease severity and regression
to the mean12,15e17. A key reason for such controversy
and confusion is that inclusion of a placebo in RCTs is
the accepted gold standard for the assessment of interven-
tion effects, and unless a no-treatment control is also in-
cluded (an approach often considered unethical) it is
impossible to ascertain what effect the placebo might
have e in effect the RCT is a way of deliberately ignoring
placebo responses9. It was because of such controversy



















Fig. 1. The effects of any treatment can be divided into ‘characteristic eff
and incidental effects (also called non-characteristic effects, context effec
combination of all the other factors affecting the outcome (box on left of d
incidental element is often larger than that of the characteristic element.
interaction between characteristic elements (e.g., muscle strengthening) a
can lead to under-estimation of the effect of an intervention if a classical R
ence between characteristic elementswas evidence for placebo response in OA RCTs, looking
speciﬁcally for trials with no treatment control groups, and
to identify possible determinants of the size of any such
effects1.Placebo effect in RCTs of OA
We identiﬁed by systematic review 198 trials that met our
inclusion criteria. These comprised 193 placebo groups
(16,364 patients) and 14 untreated control groups (1167 pa-
tients) and examined a range of non-pharmacological, phar-
macological and invasive treatments. There was clear
evidence to support positive beneﬁts from placebo. For
pain relief the overall ES (the standard mean difference be-
tween baseline and endpoint) was 0.51 [95% conﬁdence in-
terval (CI) 0.46e0.55] for placebo, but almost 0 for
untreated controls (ES 0.03, 95% CI 0.13 to 0.18). This
ES was even higher (0.77, 95% CI 0.65e0.89) in the three
trials that had head-to-head comparison between placebo
and no treatment. The ES for pain relief was also higher
(0.71, 95% CI 0.64e0.78) in the 15 trials that gave no res-
cue analgesia, perhaps reﬂecting a greater expectation of
powerful effect if no rescue was offered. Placebo was
also effective for other subjective outcomes, for example
stiffness (ES 0.43, 95% CI 0.38e0.49), self-reported func-
tion (ES 0.49, 95% CI 0.44e0.54) and interestingly, physi-
cian’s global assessment (ES 0.66, 95% CI 0.53e0.78).
With respect to determinants of magnitude, the following
showed signiﬁcant independent effects for the primary out-
come of pain relief:
The ES of the treatment: the higher the treatment ES
the higher the placebo effect, perhaps explained by
higher expectation of beneﬁt by participants.
The baseline level of pain: the higher this was, the











ects’ (the speciﬁc effects of the intervention on the target disorder),
ts, the meaning response or placebo effects), which are a complex
iagram). For problems such as pain and depression the size of the
In many complex interventions, such as physiotherapy, there is an
nd incidental elements (e.g., motivation by the physiotherapist). This
CT is used to test it, as such trial designs only measure the differ-
and non-characteristic elements.
1257Osteoarthritis and Cartilage Vol. 17, No. 10The sample size: the larger the study numbers the
higher the placebo effect. This might be explained by
the power requirements to differentiate the relatively
small additional beneﬁt of treatments over placebo.
Similarly, the funnel plot of ES for pain relief showed
a skewed distribution, suggesting that trials with
smaller placebo effects are more likely to be published,
perhaps because it is easier to demonstrate superiority
of a treatment when this occurs.
The route of delivery: RCTs involving repeated nee-
dling (acupuncture, intra-articular injection of hyalur-
onan) had the highest placebo effects (Fig. 2).
Interestingly, the one steroid injection study that gave
serial injections had a higher placebo ES than studies
involving single injection. RCTs of topical NSAID also
had higher than average placebo ES.
Such determinants provide reassurance of the validity of
our main ﬁnding. Therefore, we found unequivocal evidence
of a large placebo response in OA, particularly for pain re-
lief. Notably the ES of placebo (0.5e0.7) is much larger
than that achieved with most of our conventional therapies,
such as analgesic and anti-inﬂammatory drugs (0.2e0.3)18.
Recent publications showing similar results in depression
trials19,20 attracted widespread publicity, leading one scien-
tiﬁc author to suggest that the effectiveness of antidepres-
sants was a myth21 and some Press to wrongly conclude
that conventional therapy was of little or no value.The determinants of ‘‘placebo responses’’
Although hardly studied in OA, there is a large literature
on placebo and the non-speciﬁc effects of care in other
areas of medicine. Examples, especially from pain and
mental health studies, are worth examining here since
they are largely generic and therefore relevant to OA.
Many observations point to a major biological effect from
the way people interpret the meaning of each component
of their medical experience and the context in which it oc-
curs. The term ‘‘meaning response’’ encapsulates these ex-
planatory mechanisms, and placebo is just one example of
the responses that are integral to any clinical encounter or
treatment8,22. Although most examples relate to drugs, the
principles probably extend to any intervention.COLOUR AND NUMBERIn a classic experiment medical students were given ei-
ther one or two blue or pink tablets and told that one was
a stimulant and the other a sedative, though in fact both
were inert. Overall, pink tablets caused stimulant effects
and blue tablets sedation, and two tablets had more effect
than one23. Clearly these effects are nothing to do with re-
gression to the mean or disease ﬂuctuation, but are ex-
plained by the meaning associated with the colour (pink
for hot, blue for cool) and the expectancy that a double is
more potent than a single dose. A systematic review in
1996 concluded that green and blue may have more seda-
tive, and red and orange more stimulant effects, and that
this difference is reﬂected in the colour of marketed drugs,
perhaps boosting their efﬁcacy24. In an Italian study of sed-
ative placebos, however, blue tablets had the usual seda-
tive effect in women but the opposite effect in men25,
perhaps because blue is the national soccer team colour
and associates in men with feelings of excitement. Thus it
is not the colour per se that inﬂuences the outcome, but
the meaning attributed to it by an individual.BRANDING AND COSTHaving the conﬁdence that the treatment you are receiv-
ing is reputable and ‘‘high class’’ makes a difference to out-
come. In a placebo-controlled trial of aspirin for relief of
headache, patients were randomised to one of four treat-
ments: aspirin labelled with a well-known brand; plain un-
branded aspirin; placebo marked with the same brand; or
plain placebo. Aspirin worked better than placebo, but
branded tablets worked better than their unbranded coun-
terparts26. A recent US placebo analgesic study also
showed that patients who were told that their tablets were
obtained at full cost ($2.50) obtained better pain relief
than those who were told their tablets were discounted at
just 10 cents27.METHOD OF DELIVERY AND FREQUENCYIn general, the larger the intervention the higher the pla-
cebo effect. As in our systematic review1, greater placebo ef-
fects have been reported with injections than with oral
medication in many conditions varying from pain relief in mi-
graine28 to control of hypertension29 (Fig. 2). Also greater pla-
cebo beneﬁt from a higher frequency of administration has
been observed not just for sedation or stimulation23 but for
other conditions including healing of peptic ulcer disease30.
Surgery, of course, is one of the ultimate treatments in
terms of magnitude. In OA, the report that invasive arthro-
scopic lavage, with or without debridement, is no better
than sham procedure31 caused considerable controversy32
since it implied that the beneﬁt to the patient resulted from
the expectancy and experience of the intervention rather
than to whatever was done inside the joint. Understandably,
for ethical reasons, there are very few placebo-controlled
studies of surgery. However, in 195933 and 196034 two
small controlled studies examined the efﬁcacy of bilateral
internal mammary ligation (BIMAL) for treating angina.
This procedure was widely practiced at the time; the ratio-
nale being that ligation of these arteries would redirect
more blood through the coronary arteries. The combined re-
sults of the two studies showed that 73% of patients (24/33)
undergoing BIMAL had signiﬁcant improvement with re-
duced angina, better exercise tolerance, and reduced ni-
trate consumption. However, 83% of patients (10/12) who
received sham surgery (anaesthesia, chest incision, artery
exposed but not ligated) showed similar substantial im-
provement. Because of prevailing ethical considerations,
whether many currently performed technical procedures
give any beneﬁt above the experience of surgery itself will
remain open to question.RESPONSE EXPECTANCY AND CONCEALMENTThe expectation of what a treatment will do is an impor-
tant determinant of the outcome. In a study of aerobic exer-
cise one group was told that their aerobic capacity should
increase after 10 weeks of the programme, and the other
group was told that their ﬁtness would improve but also their
wellbeing would be enhanced. Both groups equally im-
proved aerobic capacity but only the second group reported
feeling better35. In a study of the physiological effects of cof-
fee, one group was given either regular or decaffeinated
coffee in a double blind design, while a second group was
told they would all receive regular coffee, but in fact was
given decaffeinated. Increase in pulse rate, alertness and
blood pressure changes were greater in the second group
(who were all expecting such effects) than in those given
decaffeinated coffee in the ﬁrst group (who believed they
Fig. 2. Treatments delivered by needling, such as acupuncture (shown above, with burning moxa) and intra-articular injection (shown below)
seem to associate with greater expectancy, higher placebo effects, and more ‘‘magic’’.
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sponse expectancy can even reverse the pharmacological
effect of a drug. For example, ipecachuana (a potent
emetic) can improve nausea if patients are told that they
are receiving an anti-emetic37.
Knowing that a treatment is being given is important. In
a post-operative analgesia study, patients who could see
morphine being administered into their line obtained rapid
and effective pain relief, whereas patients who receivedmor-
phine by concealed administration obtained much slower
beneﬁt, implying that the initial relief (from our strongest anal-
gesic) is largely placebo effect. Equally, open discontinuation
of morphine led to rapid return of pain whereas covert discon-
tinuation did not38. Other studies of pain, anxiety and Parkin-
son’s disease have similarly shown a decrease in treatment
efﬁcacy when the patient is unaware that they are receiving
them38. This difference between open and covert administra-
tion is equivalent to the ‘‘placebo’’ component of the treat-
ment, and investigating this difference has been suggested
as an alternative strategy, at least for some treatments, to
a classic placebo RCT design.BEHAVIOURAL CONDITIONINGIn a study of the immunosuppressive effects of cyclospor-
ine A, the drug was given to healthy volunteers together
with a novel green liquid drink. The expected degree ofimmunosuppression was observed. After ‘‘conditioning’’
the subjects in four sessions over three consecutive days,
the experiment was repeated the following week with pla-
cebo tablets given with the same drink. The repeat
exposure, with dummy tablets, resulted in immunosupres-
sion39. The authors of this work point out that although
the mechanism of such responses remains to be eluci-
dated, it might be possible to enhance the effects of immu-
nomodulatory and other drugs by behavioural conditioning
interventions e an approach that could have widespread
implications in medicine.HOW ‘NEW’ THE INTERVENTION IS?In studies of interventions for various conditions, includ-
ing depression and peptic ulcer healing, there are data to
suggest that drugs or other interventions that are ‘new’ re-
sult in larger placebo responses than those which are es-
tablished22,40, suggesting that meaning is enhanced if
patients and practitioners believe that the intervention is
‘modern’.PROVIDER EFFECTSPatients are inﬂuenced by the expectation and behaviour
of the practitioner. In a double blind dental pain study pa-
tients were told that they would receive either fentanyl
1259Osteoarthritis and Cartilage Vol. 17, No. 10(which might reduce pain), the opioid antagonist naloxone
(which might increase pain) or a placebo. However, early
in the study the investigators, but not the patients, were
told that due to administrative problems fentanyl was un-
available so patients would only be randomised to the nal-
oxone or placebo arms (i.e., only two ‘‘negative’’
treatments). Later in the study investigators were informed
that fentanyl was now available and included in the adjusted
randomisation procedure. Patients receiving placebo in the
second phase of the study experienced signiﬁcant pain re-
lief but patients on placebo in the ﬁrst phase did not41. Thus
the clinician’s optimism or pessimism concerning treatment
has a dynamic effect on the patient’s outcome.
A recent audit has shown that intentional prescribing of
‘‘placebo treatments’’, such as vitamins and over the counter
products regarded as inert, is commonplace amongst US in-
ternists and rheumatologists, and that usually these are de-
scribed to the patient as a potentially beneﬁcial treatment
not usually used for their condition42. Placebosareeven com-
mercially available in the US as ‘‘obecalp’’ (placebo spelt
backwards), ‘‘cebocap’’ (placebo capsules) and ‘‘jujubes’’
(for parents to administer to their children). However, irre-
spective of the ethical issues of not being transparent with
a patient, it would appear that placebo is less likely to give
beneﬁt when it is knowingly administered.BIOLOGICAL EFFECTS, ADHERENCE AND DEATHThere is growing evidence that context effects and mean-
ing responses can effect alterations in body systems (such
as immune function, mentioned above39) in addition to
changes in psyche and behaviour. For example, in some
pain studies placebo effects are abolished by naloxone, im-
plicating endogenous opioid release as one mechanism
that can convert expectancy to ‘‘real’’ analgesia43e45.Fig. 3. The importance of environment. A ward with a bleak view (left) elicNeuroimaging studies have made major contributions to
the ﬁeld recently46. For example, positron-emission tomog-
raphy with [11C] carfentanil has been used to provide
graphic evidence that placebo analgesia causes endoge-
nous opioid activity in the m-opioid receptor rich regions
that play a central role in pain and affect47.
The ultimate ‘‘reality’’ of placebo and meaning response is
exempliﬁed by studies of adherence and death. It is logical to
expect that people who adhere to a treatment usually do bet-
ter than non-adherers, but the same difference occurs with
placebo. In a study of antibiotic prophylaxis following chemo-
therapy48 non-adherers to placebo had twice the infection
rate of adherers (64% vs 32%), and in a study of chlorprom-
azine for schizophrenia49 non-adherers to placebo had twice
the relapse rate of adherers (80% vs 40%). This differential
outcome from adherence to placebo extends to mortality. In
a large RCT examining the effect of the cholesterol-lowering
agent cloﬁbrate on 5-year survival following myocardial in-
farction, participants who took >80% of study medications
did better than non-adherers, speciﬁcally: 15% vs 25% mor-
tality for those on cloﬁbrate; and 15%vs 28% for those on pla-
cebo50. In addition to heart disease, reduced mortality in
adherers to placebo is reported in studies of diabetes, immu-
nosuppression following transplantation, and anti-retroviral
treatment for AIDS51. Therefore adherence to what you be-
lieve to be a beneﬁcial treatment may prevent development
of disease and even death.ENVIRONMENT AND CONTEXTThe environment in which you receive treatment can
modify your outcome. Matched patients who had under-
gone gall bladder surgery were allocated to one of two
wards which were similar apart from their outlook e one
had a pleasant green-ﬁeld view and the other over-looked
a high wall and parking lot. The patients with the naturalits worse outcomes than a ward with a positive natural view (right).
Fig. 4. The difference between a positive encounter (above) and a negative encounter (below) with a practitioner can inﬂuence the outcome for
the patient. It is our professional responsibility to address such aspects.
1260 M. Doherty and P. Dieppe: ‘‘Placebo’’ response in OA e implications for clinical practiceview had fewer post-operative complications, required less
analgesia, made fewer complaints and were discharged
earlier than those with the bleak view52 (Fig. 3).
In an attempt to dissect out separate components of
placebo Kaptchuk et al. recently undertook a study of
sham acupuncture in patients with irritable bowel syn-
drome. Patients were randomised to one of three groups:
waiting list (assessment and observation); sham acupunc-
ture with only limited patientepractitioner interaction (the
therapeutic ‘‘ritual’’); or sham acupuncture with more
usual patientepractitioner interaction augmented by
warmth, attention and conﬁdence. At 3 weeks the propor-
tions in each group with adequate pain relief were 28%
(observation), 44% (ritual) and 62% (augmented interac-
tion). A similar trend was observed for quality of life
(3.6, 4.1, 9.3) and all other measured outcomes53. Clearly
all three components contributed to beneﬁt but the most
robust was patientepractitioner interaction.
The importance of the patientepractitioner interaction
was also the focus of a study in general practice in which
200 patients with symptoms but no abnormal signs were
randomly assigned to either: (1) a ‘‘positive’’ consultation,
in which the patient was given a conﬁdent diagnosis and re-
assured that things would soon improve; or (2) a ‘‘negative’’
consultation, where the doctor admitted ‘‘I cannot be certain
of what is the matter with you’’. In both groups the doctor
could also prescribe thiamine tablets as ‘‘placebo’’ medica-
tion. Two weeks later, 64% of patients who had the positiveconsult were better, compared to 39% of those who had the
negative encounter. Receiving a prescription made no dif-
ference. The overriding factor appeared to be the patient re-
sponse to the certainty of diagnosis and reassurance
concerning prognosis54. Other contextual aspects that are
suggested to encourage a beneﬁcial meaning response in-
clude: when the patient regards the practitioner as experi-
enced and competent55,56; when the clinician is optimistic
that the treatment will help55,56 and when the practitioner
wishes to see the patient again to monitor progress57.
Implications for clinical practice
OA is a condition in which the pathology does not always
correlate with the symptoms58. Thus someone may have
severe joint damage but no pain, or severe pain but only
minor joint pathology. As outlined above, placebo re-
sponses can result in big effects on symptoms (the illness),
but we have not found evidence that they affect X-rays and
pathology (the disease). The fact that placebo responses
are best documented in other painful conditions and in
mental health disorders, suggests that the value of placebo
interventions is mainly for patient symptoms and distress.
These are the principal treatment targets in patients with
OA. We believe that we should be more aware of the
power of the placebo response to relieve pain and suffering
in people with OA, and that we should learn how to use it
better.
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ical encounter many facets of the patient’s experience de-
termine their outcome from any intervention. In audits of
care, including OA59, common patient complaints are:
that the doctor was ‘‘too busy’’ to listen,
that the doctor undertakes only a superﬁcial examina-
tion, or no examination at all,
that the doctor didn’t address key concerns,
that the doctor did not give a follow-up appointment.
Given these circumstances it is obvious that practitioners
should capitalise on the impact of context effects to en-
hance the beneﬁts to their patients, as a professional re-
sponsibility. Many of these aspects are nothing to do with
the ‘‘ritual’’ of a drug or physical treatment. When a practi-
tioner gives a patient their focused and unhurried attention
in a comfortable environment, listens to them, undertakes
a thorough examination, explains in understandable terms
what is happening, addresses concerns and provides
a way forward, the patient experiences a ‘‘good deal’’.
This is in itself a treatment (Fig. 4). The patient often leaves
both looking and feeling better, long before they cash in any
(adjunctive) prescription they have just received. The con-
verse is also true. Recent studies of the ‘‘nocebo’’ effect
(expectation of a negative effect leading to worse outcome)
have shown, for example, that negative words that increase
anxiety can result in increased pain60.
The use of the term ‘meaning response’ to cover what we
have here called non-characteristic or context effects8,22 em-
phasises the importance of themeaning of a consultation and
any suggested intervention to the patient. The meanings of
interventions are culturally determined and depend in part
on the health beliefs of the patient. Exorcismmay work better
thanaspirin if a patient ﬁrmly believes that their pain is caused
by their possession by evil spirits61. Health beliefs can be eli-
cited in a clinical encounter, and measured for research pur-
poses62. Furthermore, in many cases practitioners can help
the patient towards a health belief that is more in tune with
the interventions that are available to help them.
Practitioners of complementary and alternative medicine
(CAM) often do this very well, and seem ahead of many
of us more traditional physicians. We often pride ourselves
on being over-worked and too busy to spend time on such
‘‘peripheral’’ matters, and feel more useful and important
when we exercise our licence to prescribe potentially dan-
gerous drugs. We often label practitioners of CAM as char-
latans and explain their treatment success as ‘‘just placebo
effect’’, apparently oblivious of the surprisingly large ES of
such ‘‘non-treatment’’ beneﬁts. But if we did learn from the
research literature, from practitioners of CAM, and from sim-
ple observation, and optimise these meaning responses8,22
in our clinical practice, the beneﬁts of such ‘‘contextual heal-
ing’’7 to the population of people with OA would be huge.Conﬂict of interest
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